{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T05:45:30Z","timestamp":1783662330421,"version":"3.55.0"},"reference-count":128,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T00:00:00Z","timestamp":1695254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>The estrogen receptor (ER) is a classical receptor protein that plays a crucial role in mediating multiple signaling pathways in various target organs. It has been shown that ER-targeting therapies inhibit breast cancer cell proliferation, enhance neuronal protection, and promote osteoclast formation. Several drugs have been designed to specifically target ER in ER-positive (ER+) breast cancer, including selective estrogen receptor modulators (SERM) such as Tamoxifen. However, the emergence of drug resistance in ER+ breast cancer and the potential side effects on the endometrium which has high ER expression has posed significant challenges in clinical practice. Recently, novel ER-targeted drugs, namely, selective estrogen receptor degrader (SERD) and selective estrogen receptor covalent antagonist (SERCA) have shown promise in addressing these concerns. This paper provides a comprehensive review of the structural functions of ER and highlights recent advancements in SERD and SERCA-related small molecule drugs, especially focusing on their structural optimization strategies and future optimization directions. Additionally, the therapeutic potential and challenges of novel SERDs and SERCAs in breast cancer and other ER-related diseases have been discussed.<\/jats:p>","DOI":"10.3389\/fphar.2023.1225951","type":"journal-article","created":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T07:52:13Z","timestamp":1695369133000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Optimization of small molecule degraders and antagonists for targeting estrogen receptor based on breast cancer: current status and future"],"prefix":"10.3389","volume":"14","author":[{"given":"Jiaqi","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiran","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zelin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,21]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.1523\/JNEUROSCI.22-09-03608.2002","article-title":"Estrogen and aging affect the subcellular distribution of estrogen receptor-alpha in the hippocampus of female rats","volume":"22","author":"Adams","year":"2002","journal-title":"J. Neurosci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"4812","DOI":"10.3390\/ijms21134812","article-title":"Steroids and alzheimer's disease: Changes associated with pathology and therapeutic potential","volume":"21","author":"Akwa","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1152\/physrev.00033.2015","article-title":"Estrogens and androgens in skeletal physiology and pathophysiology","volume":"97","author":"Almeida","year":"2017","journal-title":"Physiol. Rev."},{"key":"B4","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s10549-020-05575-9","article-title":"G1T48, an oral selective estrogen receptor degrader, and the CDK4\/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer","volume":"180","author":"Andreano","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"key":"B5","doi-asserted-by":"publisher","first-page":"8495","DOI":"10.1074\/jbc.RA117.001212","article-title":"The F domain of estrogen receptor \u03b1 is involved in species-specific, tamoxifen-mediated transactivation","volume":"293","author":"Arao","year":"2018","journal-title":"J. Biol. Chem."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e202103926","DOI":"10.1002\/chem.202103926","article-title":"Direct superacid-promoted difluoroethylation of aromatics","volume":"28","author":"Artault","year":"2022","journal-title":"Chemistry"},{"key":"B7","doi-asserted-by":"publisher","first-page":"113543","DOI":"10.1016\/j.ejmech.2021.113543","article-title":"Design and synthesis of novel benzothiophene analogs as selective estrogen receptor covalent antagonists against breast cancer","volume":"221","author":"Bai","year":"","journal-title":"Eur. J. Med. Chem."},{"key":"B8","doi-asserted-by":"publisher","first-page":"116395","DOI":"10.1016\/j.bmc.2021.116395","article-title":"Benzothiophene derivatives as selective estrogen receptor covalent antagonists: Design, synthesis and anti-ER\u03b1 activities","volume":"47","author":"Bai","year":"","journal-title":"Bioorg Med. Chem."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2011.03.008","article-title":"Insights from the structure of estrogen receptor into the evolution of estrogens: Implications for endocrine disruption","volume":"82","author":"Baker","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.lfs.2011.03.010","article-title":"The possible role of estrogen and selective estrogen receptor modulators in a rat model of Parkinson's disease","volume":"88","author":"Baraka","year":"2011","journal-title":"Life Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1517\/13543784.2016.1154532","article-title":"Fulvestrant for the treatment of endometrial cancer","volume":"25","author":"Battista","year":"2016","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B12","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s12032-023-02045-2","article-title":"Elacestrant: A new FDA-approved SERD for the treatment of breast cancer","volume":"40","author":"Bhatia","year":"2023","journal-title":"Med. Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"8109","DOI":"10.1038\/sj.onc.1204917","article-title":"Quantification of estrogen receptor alpha and beta expression in sporadic breast cancer","volume":"20","author":"Bi\u00e8che","year":"2001","journal-title":"Oncogene"},{"key":"B14","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/BF03032403","article-title":"Immunohistochemical analysis of c-myc, c-jun and estrogen receptor in normal, hyperplastic and neoplastic endometrium","volume":"11","author":"Bircan","year":"2005","journal-title":"Pathol. Oncol. Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1080\/17425255.2016.1244264","article-title":"The role of fulvestrant in endometrial cancer","volume":"13","author":"Bogliolo","year":"2017","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13058-021-01462-3","article-title":"ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer","volume":"23","author":"Brett","year":"2021","journal-title":"Breast Cancer Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/39645","article-title":"Molecular basis of agonism and antagonism in the oestrogen receptor","volume":"389","author":"Brzozowski","year":"1997","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1055\/s-2004-823026","article-title":"Aromatase and endometriosis","volume":"22","author":"Bulun","year":"2004","journal-title":"Semin. Reprod. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.cell.2019.11.031","article-title":"Proteolysis-targeting chimeras as therapeutics and tools for biological discovery","volume":"181","author":"Burslem","year":"2020","journal-title":"Cell."},{"key":"B20","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.chembiol.2017.09.009","article-title":"The advantages of targeted protein degradation over inhibition: An RTK case study","volume":"25","author":"Burslem","year":"2018","journal-title":"Cell. Chem. Biol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1046\/j.0022-3042.2001.00693.x","article-title":"Evaluation of the protective effect of oestradiol against toxicity induced by 6-hydroxydopamine and 1-methyl-4-phenylpyridinium ion (Mpp+) towards dopaminergic mesencephalic neurones in primary culture","volume":"80","author":"Callier","year":"2002","journal-title":"J. Neurochem."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1210\/en.2007-1346","article-title":"Selective estrogen receptor modulators differentially regulate Alzheimer-like changes in female 3xTg-AD mice","volume":"149","author":"Carroll","year":"2008","journal-title":"Endocrinology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","article-title":"Antibody-drug conjugates for cancer","volume":"394","author":"Chau","year":"2019","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1080\/13543784.2021.1983542","article-title":"Latest generation estrogen receptor degraders for the treatment of hormone receptor-positive breast cancer","volume":"31","author":"Chen","year":"2022","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B25","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1021\/acs.jmedchem.7b01272","article-title":"Protac-induced protein degradation in drug discovery: Breaking the rules or just making new ones?","volume":"61","author":"Churcher","year":"2018","journal-title":"J. Med. Chem."},{"key":"B26","doi-asserted-by":"publisher","first-page":"19858","DOI":"10.1074\/jbc.272.32.19858","article-title":"Estrogen receptors alpha and beta form heterodimers on DNA","volume":"272","author":"Cowley","year":"1997","journal-title":"J. Biol. Chem."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1002\/j.1460-2075.1992.tb05141.x","article-title":"Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors","volume":"11","author":"Danielian","year":"1992","journal-title":"Embo J."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/j.neuropharm.2004.08.020","article-title":"Effect of estrogen receptor agonists treatment in MPTP mice: Evidence of neuroprotection by an ER alpha agonist","volume":"47","author":"D'Astous","year":"2004","journal-title":"Neuropharmacology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"8128","DOI":"10.1021\/acs.jmedchem.5b00984","article-title":"Optimization of a novel binding motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid (AZD9496), a potent and orally bioavailable selective estrogen receptor downregulator and antagonist","volume":"58","author":"De Savi","year":"2015","journal-title":"J. Med. Chem."},{"key":"B30","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.abb.2011.01.002","article-title":"Genetic variations within the ERE motif modulate plasticity and energetics of binding of DNA to the ER\u03b1 nuclear receptor","volume":"507","author":"Deegan","year":"2011","journal-title":"Arch. Biochem. Biophys."},{"key":"B31","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.steroids.2014.07.012","article-title":"Ospemifene: A first-in-class, non-hormonal selective estrogen receptor modulator approved for the treatment of dyspareunia associated with vulvar and vaginal atrophy","volume":"90","author":"DeGregorio","year":"2014","journal-title":"Steroids"},{"key":"B32","doi-asserted-by":"publisher","first-page":"127601","DOI":"10.1016\/j.bmcl.2020.127601","article-title":"Design, syntheses and evaluations of novel indole derivatives as orally selective estrogen receptor degraders (SERD)","volume":"30","author":"Dong","year":"2020","journal-title":"Bioorg Med. Chem. Lett."},{"key":"B33","doi-asserted-by":"publisher","first-page":"3714","DOI":"10.1002\/cncr.32345","article-title":"ESR1 mutations in breast cancer","volume":"125","author":"Dustin","year":"2019","journal-title":"Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"16069","DOI":"10.1038\/nrdp.2016.69","article-title":"Postmenopausal osteoporosis","volume":"2","author":"Eastell","year":"2016","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B35","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1021\/acs.jmedchem.9b01293","article-title":"Discovery of 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid (SAR439859), a potent and selective estrogen receptor degrader (SERD) for the treatment of estrogen-receptor-positive breast cancer","volume":"63","author":"El-Ahmad","year":"2020","journal-title":"J. Med. Chem."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4939-3127-9_1","article-title":"The estrogen receptors: An overview from different perspectives","volume":"1366","author":"Eyster","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1158\/0008-5472.CAN-18-3634","article-title":"Estrogen receptor covalent antagonists: The best is yet to come","volume":"79","author":"Furman","year":"2019","journal-title":"Cancer Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1158\/1535-7163.MCT-21-0378","article-title":"Covalent ER\u03b1 antagonist H3B-6545 demonstrates encouraging preclinical activity in therapy-resistant breast cancer","volume":"21","author":"Furman","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"B39","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41587-021-01173-2","article-title":"The PROTAC gold rush","volume":"40","author":"Garber","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jpba.2019.04.045","article-title":"Pharmacokinetics and metabolism of H3B-6545, a selective estrogen receptor covalent antagonist, in dog plasma by liquid chromatography combined with electrospray ionization tandem mass spectrometry","volume":"172","author":"Ge","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"B41","doi-asserted-by":"publisher","first-page":"100882","DOI":"10.1016\/j.esmoop.2023.100882","article-title":"How I treat endocrine-dependent metastatic breast cancer","volume":"8","author":"Gombos","year":"2023","journal-title":"ESMO Open"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1126\/science.3753802","article-title":"Sequence and expression of human estrogen receptor complementary DNA","volume":"231","author":"Greene","year":"1986","journal-title":"Science"},{"key":"B43","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s10549-020-05558-w","article-title":"GLL398, an oral selective estrogen receptor degrader (SERD), blocks tumor growth in xenograft breast cancer models","volume":"180","author":"Guo","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"key":"B44","doi-asserted-by":"publisher","first-page":"S36","DOI":"10.1016\/s0959-8049(22)00896-6","article-title":"Phase 1b results from OP-1250-001, a dose escalation and dose expansion study of OP-1250, an oral CERAN, in subjects with advanced and\/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer (NCT04505826)","volume":"174","author":"Hamilton","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"B45","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","article-title":"Breast cancer","volume":"5","author":"Harbeck","year":"2019","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B46","doi-asserted-by":"publisher","first-page":"17476","DOI":"10.1016\/s0021-9258(18)71519-6","article-title":"Identification of cysteine 530 as the covalent attachment site of an affinity-labeling estrogen (ketononestrol aziridine) and antiestrogen (tamoxifen aziridine) in the human estrogen receptor","volume":"264","author":"Harlow","year":"1989","journal-title":"J. Biol. Chem."},{"key":"B47","doi-asserted-by":"publisher","first-page":"7812","DOI":"10.3390\/ijms22157812","article-title":"Oral selective estrogen receptor degraders (SERDs) as a novel breast cancer therapy: Present and future from a clinical perspective","volume":"22","author":"Hernando","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B48","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41416-021-01564-x","article-title":"ESR1 mutations and therapeutic resistance in metastatic breast cancer: Progress and remaining challenges","volume":"126","author":"Herzog","year":"2022","journal-title":"Br. J. Cancer"},{"key":"B49","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/j.1525-1438.2005.15321.x","article-title":"Expression of estrogen receptors ERalpha and ERbeta in endometrial hyperplasia and adenocarcinoma","volume":"15","author":"Hu","year":"2005","journal-title":"Int. J. Gynecol. Cancer"},{"key":"B50","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1148\/radiol.2018171118","article-title":"Receptor-based surrogate subtypes and discrepancies with breast cancer intrinsic subtypes: Implications for image biomarker development","volume":"289","author":"Jamshidi","year":"2018","journal-title":"Radiology"},{"key":"B51","doi-asserted-by":"publisher","first-page":"5760","DOI":"10.1158\/1078-0432.CCR-21-1095","article-title":"A phase I study of LSZ102, an oral selective estrogen receptor degrader, with or without ribociclib or alpelisib, in patients with estrogen receptor-positive breast cancer","volume":"27","author":"Jhaveri","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"B52","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1470-2045(00)00009-7","article-title":"Tamoxifen: A personal retrospective","volume":"1","author":"Jordan","year":"2000","journal-title":"Lancet Oncol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2174\/1389200054021799","article-title":"A comprehensive listing of bioactivation pathways of organic functional groups","volume":"6","author":"Kalgutkar","year":"2005","journal-title":"Curr. Drug Metab."},{"key":"B54","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.tem.2012.03.008","article-title":"Estrogen and the skeleton","volume":"23","author":"Khosla","year":"2012","journal-title":"Trends Endocrinol. Metab."},{"key":"B55","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.pharmthera.2012.03.007","article-title":"Estrogen and the cardiovascular system","volume":"135","author":"Knowlton","year":"2012","journal-title":"Pharmacol. Ther."},{"key":"B56","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1210\/me.2006-0203","article-title":"Identification of regions within the F domain of the human estrogen receptor alpha that are important for modulating transactivation and protein-protein interactions","volume":"21","author":"Koide","year":"2007","journal-title":"Mol. Endocrinol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jphs.2016.06.005","article-title":"Ameliorative effect of membrane-associated estrogen receptor G protein coupled receptor 30 activation on object recognition memory in mouse models of Alzheimer's disease","volume":"131","author":"Kubota","year":"2016","journal-title":"J. Pharmacol. Sci."},{"key":"B58","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ymeth.2014.07.007","article-title":"Hierarchical virtual screening approaches in small molecule drug discovery","volume":"71","author":"Kumar","year":"2015","journal-title":"Methods"},{"key":"B59","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1021\/jm960255g","article-title":"Conformational studies and electronic structures of tamoxifen and toremifene and their allylic carbocations proposed as reactive intermediates leading to DNA adduct formation","volume":"39","author":"Kuramochi","year":"1996","journal-title":"J. Med. Chem."},{"key":"B60","doi-asserted-by":"publisher","first-page":"54120","DOI":"10.18632\/oncotarget.10852","article-title":"Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations","volume":"7","author":"Ladd","year":"2016","journal-title":"Oncotarget"},{"key":"B61","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrd.2016.211","article-title":"Induced protein degradation: An emerging drug discovery paradigm","volume":"16","author":"Lai","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"B62","doi-asserted-by":"publisher","first-page":"4888","DOI":"10.1021\/acs.jmedchem.5b00054","article-title":"Identification of GDC-0810 (ARN-810), an orally bioavailable selective estrogen receptor degrader (SERD) that demonstrates robust activity in tamoxifen-resistant breast cancer xenografts","volume":"58","author":"Lai","year":"2015","journal-title":"J. Med. Chem."},{"key":"B63","doi-asserted-by":"publisher","first-page":"e12961","DOI":"10.1111\/acel.12961","article-title":"Estrogen receptor \u03b1 promotes Cav1.2 ubiquitination and degradation in neuronal cells and in APP\/PS1 mice","volume":"18","author":"Lai","year":"2019","journal-title":"Aging Cell."},{"key":"B64","doi-asserted-by":"publisher","first-page":"101686","DOI":"10.18632\/oncotarget.21514","article-title":"The expression of cystathionine gamma-lyase is regulated by estrogen receptor alpha in human osteoblasts","volume":"8","author":"Lambertini","year":"2017","journal-title":"Oncotarget"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1021\/acsmedchemlett.0c00224","article-title":"Discovery of GNE-149 as a full antagonist and efficient degrader of estrogen receptor alpha for ER+ breast cancer","volume":"11","author":"Liang","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"B66","doi-asserted-by":"publisher","first-page":"11841","DOI":"10.1021\/acs.jmedchem.1c00847","article-title":"GDC-9545 (giredestrant): A potent and orally bioavailable selective estrogen receptor antagonist and degrader with an exceptional preclinical profile for ER+ breast cancer","volume":"64","author":"Liang","year":"2021","journal-title":"J. Med. Chem."},{"key":"B67","doi-asserted-by":"publisher","first-page":"112689","DOI":"10.1016\/j.ejmech.2020.112689","article-title":"Targeting estrogen receptor \u03b1 for degradation with PROTACs: A promising approach to overcome endocrine resistance","volume":"206","author":"Lin","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"B68","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1021\/tx049776u","article-title":"Bioactivation of the selective estrogen receptor modulator desmethylated arzoxifene to quinoids: 4'-fluoro substitution prevents quinoid formation","volume":"18","author":"Liu","year":"2005","journal-title":"Chem. Res. Toxicol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"8134","DOI":"10.1021\/acs.jmedchem.6b00753","article-title":"Fulvestrant-3 boronic acid (ZB716): An orally bioavailable selective estrogen receptor downregulator (SERD)","volume":"59","author":"Liu","year":"2016","journal-title":"J. Med. Chem."},{"key":"B70","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1021\/acsmedchemlett.6b00410","article-title":"Rational design of a boron-modified triphenylethylene (GLL398) as an oral selective estrogen receptor downregulator","volume":"8","author":"Liu","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"B71","doi-asserted-by":"publisher","first-page":"719","DOI":"10.3390\/ph14080719","article-title":"Fulvestrant-3-Boronic acid (ZB716) demonstrates oral bioavailability and favorable pharmacokinetic profile in preclinical ADME studies","volume":"14","author":"Liu","year":"2021","journal-title":"Pharm. (Basel)"},{"key":"B72","doi-asserted-by":"publisher","first-page":"103666","DOI":"10.1016\/j.bioorg.2020.103666","article-title":"A new class of 1,3,5-triazine-based selective estrogen receptor degraders (SERDs): Lead optimization, molecular docking and dynamic simulation","volume":"97","author":"Lu","year":"2020","journal-title":"Bioorg Chem."},{"key":"B73","doi-asserted-by":"publisher","first-page":"104714","DOI":"10.1016\/j.bioorg.2021.104714","article-title":"Discovery of novel 2H-chromene-3-carbonyl derivatives as selective estrogen receptor degraders (SERDs): Design, synthesis and biological evaluation","volume":"109","author":"Lu","year":"2021","journal-title":"Bioorg Chem."},{"key":"B74","doi-asserted-by":"publisher","first-page":"128734","DOI":"10.1016\/j.bmcl.2022.128734","article-title":"Discovery and preclinical profile of LX-039, a novel indole-based oral selective estrogen receptor degrader (SERD)","volume":"66","author":"Lu","year":"","journal-title":"Bioorg Med. Chem. Lett."},{"key":"B75","doi-asserted-by":"publisher","first-page":"5724","DOI":"10.1021\/acs.jmedchem.2c00008","article-title":"Discovery of thieno[2,3-e]indazole derivatives as novel oral selective estrogen receptor degraders with highly improved antitumor effect and favorable druggability","volume":"65","author":"Lu","year":"","journal-title":"J. Med. Chem."},{"key":"B76","doi-asserted-by":"publisher","first-page":"106731","DOI":"10.1016\/j.phrs.2023.106731","article-title":"SERD-NHC-Au(I) complexes for dual targeting ER and TrxR to induce ICD in breast cancer","volume":"190","author":"Lu","year":"2023","journal-title":"Pharmacol. Res."},{"key":"B77","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s10549-005-7697-7","article-title":"Estrogen receptor beta (ESR2) polymorphisms in familial and sporadic breast cancer","volume":"94","author":"Maguire","year":"2005","journal-title":"Breast Cancer Res. Treat."},{"key":"B78","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.coph.2009.08.004","article-title":"Novel trends in high-throughput screening","volume":"9","author":"Mayr","year":"2009","journal-title":"Curr. Opin. Pharmacol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1159\/000338400","article-title":"Membrane estrogen receptor regulation of hypothalamic function","volume":"96","author":"Micevych","year":"2012","journal-title":"Neuroendocrinology"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1037531","DOI":"10.3389\/fonc.2022.1037531","article-title":"ESR1 fusions and therapeutic resistance in metastatic breast cancer","volume":"12","author":"Nagy","year":"2022","journal-title":"Front. Oncol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.1016\/j.breast.2015.07.015","article-title":"The changing role of ER in endocrine resistance","volume":"24","author":"Nardone","year":"2015","journal-title":"Breast"},{"key":"B82","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/nchembio.76","article-title":"NFkappaB selectivity of estrogen receptor ligands revealed by comparative crystallographic analyses","volume":"4","author":"Nettles","year":"2008","journal-title":"Nat. Chem. Biol."},{"key":"B83","first-page":"5771","article-title":"Re-expression of estrogen receptor alpha in estrogen receptor alpha-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth","volume":"61","author":"Oesterreich","year":"2001","journal-title":"Cancer Res."},{"key":"B84","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s004180050342","article-title":"Expression of estrogen receptor-alpha in cells of the osteoclastic lineage","volume":"111","author":"Oreffo","year":"1999","journal-title":"Histochem Cell. Biol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1146\/annurev-med-070909-182917","article-title":"Mechanisms of endocrine resistance in breast cancer","volume":"62","author":"Osborne","year":"2011","journal-title":"Annu. Rev. Med."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2017.12.012","article-title":"Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment","volume":"186","author":"Patel","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"B87","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/s0960-0760(00)00102-3","article-title":"A structural biologist's view of the oestrogen receptor","volume":"74","author":"Pike","year":"2000","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1158\/2159-8290.CD-17-1229","article-title":"Discovery of selective estrogen receptor covalent antagonists for the treatment of ER\u03b1WT and ER\u03b1MUT breast cancer","volume":"8","author":"Puyang","year":"2018","journal-title":"Cancer Discov."},{"key":"B89","doi-asserted-by":"publisher","first-page":"692574","DOI":"10.3389\/fphar.2021.692574","article-title":"Protac: An effective targeted protein degradation strategy for cancer therapy","volume":"12","author":"Qi","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s13018-023-03660-5","article-title":"ERK-estrogen receptor \u03b1 signaling plays a role in the process of bone marrow mesenchymal stem cell-derived exosomes protecting against ovariectomy-induced bone loss","volume":"18","author":"Qi","year":"2023","journal-title":"J. Orthop. Surg. Res."},{"key":"B91","doi-asserted-by":"publisher","first-page":"10880","DOI":"10.1016\/s0021-9258(18)99101-5","article-title":"Mutagenesis of cysteines in the hormone binding domain of the human estrogen receptor. Alterations in binding and transcriptional activation by covalently and reversibly attaching ligands","volume":"266","author":"Reese","year":"1991","journal-title":"J. Biol. Chem."},{"key":"B92","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.soncn.2015.02.002","article-title":"Endocrine therapy in breast cancer: The neoadjuvant, adjuvant, and metastatic approach","volume":"31","author":"Reinbolt","year":"2015","journal-title":"Semin. Oncol. Nurs."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.4155\/fmc.15.70","article-title":"Ligand efficiency metrics: Why all the fuss?","volume":"7","author":"Reynolds","year":"2015","journal-title":"Future Med. Chem."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1126\/science.aam7340","article-title":"Waste disposal-An attractive strategy for cancer therapy","volume":"355","author":"Salami","year":"2017","journal-title":"Science"},{"key":"B95","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1080\/13543776.2022.2006185","article-title":"Selective estrogen receptor degraders (SERDs) and covalent antagonists (SERCAs): A patent review (2015-present)","volume":"32","author":"Scott","year":"2022","journal-title":"Expert Opin. Ther. Pat."},{"key":"B96","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1021\/acsmedchemlett.5b00413","article-title":"Tetrahydroisoquinoline phenols: Selective estrogen receptor downregulator antagonists with oral bioavailability in rat","volume":"7","author":"Scott","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"B97","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1021\/acs.jmedchem.8b01837","article-title":"Tricyclic indazoles-A novel class of selective estrogen receptor degrader antagonists","volume":"62","author":"Scott","year":"2019","journal-title":"J. Med. Chem."},{"key":"B98","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1158\/2159-8290.CD-NB2023-0005","article-title":"Second oral SERD shines in ER+ breast cancer","volume":"13","year":"2023","journal-title":"Cancer Discov."},{"key":"B99","doi-asserted-by":"publisher","first-page":"11837","DOI":"10.1021\/acs.jmedchem.1c01268","article-title":"A new era in ER+ breast cancer: Best-in-Class oral selective estrogen receptor degrader (SERD) designed as an endocrine backbone treatment","volume":"64","author":"Shao","year":"2021","journal-title":"J. Med. Chem."},{"key":"B100","doi-asserted-by":"publisher","first-page":"5247","DOI":"10.1021\/jm4006059","article-title":"Optimization of ligand and lipophilic efficiency to identify an in vivo active furano-pyrimidine Aurora kinase inhibitor","volume":"56","author":"Shiao","year":"2013","journal-title":"J. Med. Chem."},{"key":"B101","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1158\/1535-7163.MCT-20-0390","article-title":"SAR439859, a novel selective estrogen receptor degrader (SERD), demonstrates effective and broad antitumor activity in wild-type and mutant ER-positive breast cancer models","volume":"20","author":"Shomali","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"B102","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/s0306-4522(99)00520-5","article-title":"Estrogen binding and estrogen receptor characterization (ERalpha and ERbeta) in the cholinergic neurons of the rat basal forebrain","volume":"96","author":"Shughrue","year":"2000","journal-title":"Neuroscience"},{"key":"B103","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"B104","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1080\/14656566.2019.1651293","article-title":"An evaluation of fulvestrant for the treatment of metastatic breast cancer","volume":"20","author":"Soleja","year":"2019","journal-title":"Expert Opin. Pharmacother."},{"key":"B105","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/cge.13900","article-title":"Molecular intrinsic versus clinical subtyping in breast cancer: A comprehensive review","volume":"99","author":"Szymiczek","year":"2021","journal-title":"Clin. Genet."},{"key":"B106","doi-asserted-by":"publisher","first-page":"105967","DOI":"10.1016\/j.phrs.2021.105967","article-title":"Urolithin A suppresses RANKL-induced osteoclastogenesis and postmenopausal osteoporosis by, suppresses inflammation and downstream NF-\u03baB activated pyroptosis pathways","volume":"174","author":"Tao","year":"2021","journal-title":"Pharmacol. Res."},{"key":"B107","doi-asserted-by":"publisher","first-page":"8391","DOI":"10.1523\/JNEUROSCI.22-19-08391.2002","article-title":"ER-X: A novel, plasma membrane-associated, putative estrogen receptor that is regulated during development and after ischemic brain injury","volume":"22","author":"Toran-Allerand","year":"2002","journal-title":"J. Neurosci."},{"key":"B108","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1021\/acs.jmedchem.7b01682","article-title":"Discovery of LSZ102, a potent, orally bioavailable selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive breast cancer","volume":"61","author":"Tria","year":"2018","journal-title":"J. Med. Chem."},{"key":"B109","doi-asserted-by":"publisher","first-page":"559","DOI":"10.2217\/fon-2022-1196","article-title":"Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment","volume":"19","author":"Turner","year":"2023","journal-title":"Future Oncol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.steroids.2018.01.010","article-title":"Membrane-initiated estrogen signaling via Gq-coupled GPCR in the central nervous system","volume":"142","author":"Vail","year":"2019","journal-title":"Steroids"},{"key":"B111","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1001\/jama.2018.20751","article-title":"Breast cancer treatment","volume":"321","author":"Waks","year":"2019","journal-title":"Jama"},{"key":"B112","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s10555-022-10066-y","article-title":"The race to develop oral SERDs and other novel estrogen receptor inhibitors: Recent clinical trial results and impact on treatment options","volume":"41","author":"Wang","year":"2022","journal-title":"Cancer Metastasis Rev."},{"key":"B113","doi-asserted-by":"publisher","first-page":"5121","DOI":"10.1158\/1078-0432.CCR-15-0360","article-title":"Efficacy of SERD\/SERM hybrid-CDK4\/6 inhibitor combinations in models of endocrine therapy-resistant breast cancer","volume":"21","author":"Wardell","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"B114","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1158\/0008-5472.CAN-15-2357","article-title":"AZD9496: An oral estrogen receptor inhibitor that blocks the growth of ER-positive and ESR1-mutant breast tumors in preclinical models","volume":"76","author":"Weir","year":"2016","journal-title":"Cancer Res."},{"key":"B115","doi-asserted-by":"publisher","first-page":"20211033","DOI":"10.1259\/bjr.20211033","article-title":"Understanding breast cancer as a global health concern","volume":"95","author":"Wilkinson","year":"2022","journal-title":"Br. J. Radiol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"3901","DOI":"10.1210\/endo.138.9.5358","article-title":"Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone","volume":"138","author":"Willson","year":"1997","journal-title":"Endocrinology"},{"key":"B117","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.molcel.2005.04.014","article-title":"Structural basis for an unexpected mode of SERM-mediated ER antagonism","volume":"18","author":"Wu","year":"2005","journal-title":"Mol. Cell."},{"key":"B118","doi-asserted-by":"publisher","first-page":"6631","DOI":"10.1021\/acs.jmedchem.2c02032","article-title":"Discovery of a novel class of PROTACs as potent and selective estrogen receptor \u03b1 degraders to overcome endocrine-resistant breast cancer in vitro and in vivo","volume":"66","author":"Xie","year":"2023","journal-title":"J. Med. Chem."},{"key":"B119","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1021\/acs.jmedchem.5b01276","article-title":"Selective human estrogen receptor partial agonists (ShERPAs) for tamoxifen-resistant breast cancer","volume":"59","author":"Xiong","year":"2016","journal-title":"J. Med. Chem."},{"key":"B120","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1021\/acs.jmedchem.6b01355","article-title":"Novel selective estrogen receptor downregulators (SERDs) developed against treatment-resistant breast cancer","volume":"60","author":"Xiong","year":"2017","journal-title":"J. Med. Chem."},{"key":"B121","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1080\/14656566.2019.1615882","article-title":"Bazedoxifene for the treatment of osteoporosis","volume":"20","author":"Yavropoulou","year":"2019","journal-title":"Expert Opin. Pharmacother."},{"key":"B122","doi-asserted-by":"publisher","first-page":"4136","DOI":"10.1111\/bph.14531","article-title":"Oestradiol influences on dopamine release from the nucleus accumbens shell: Sex differences and the role of selective oestradiol receptor subtypes","volume":"176","author":"Yoest","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"827724","DOI":"10.3389\/fendo.2022.827724","article-title":"Estrogen receptor function: Impact on the human endometrium","volume":"13","author":"Yu","year":"2022","journal-title":"Front. Endocrinol. (Lausanne)."},{"key":"B124","doi-asserted-by":"publisher","first-page":"128335","DOI":"10.1016\/j.bmcl.2021.128335","article-title":"Discovery of GNE-502 as an orally bioavailable and potent degrader for estrogen receptor positive breast cancer","volume":"50","author":"Zbieg","year":"2021","journal-title":"Bioorg Med. Chem. Lett."},{"key":"B125","doi-asserted-by":"publisher","first-page":"687244","DOI":"10.3389\/fendo.2021.687244","article-title":"The role of Ki67 in evaluating neoadjuvant endocrine therapy of hormone receptor-positive breast cancer","volume":"12","author":"Zhang","year":"","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B126","doi-asserted-by":"publisher","first-page":"7575","DOI":"10.1021\/acs.jmedchem.1c00280","article-title":"Dynamics-based discovery of novel, potent benzoic acid derivatives as orally bioavailable selective estrogen receptor degraders for ER\u03b1+ breast cancer","volume":"64","author":"Zhang","year":"","journal-title":"J. Med. Chem."},{"key":"B127","doi-asserted-by":"publisher","first-page":"eabf5473","DOI":"10.1126\/scitranslmed.abf5473","article-title":"CECR2 drives breast cancer metastasis by promoting NF-\u03baB signaling and macrophage-mediated immune suppression","volume":"14","author":"Zhang","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"B128","doi-asserted-by":"publisher","first-page":"104294","DOI":"10.1016\/j.phrs.2019.104294","article-title":"Sesterterpene MHO7 suppresses breast cancer cells as a novel estrogen receptor degrader","volume":"146","author":"Zhao","year":"2019","journal-title":"Pharmacol. Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1225951\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T07:52:15Z","timestamp":1695369135000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1225951\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,21]]},"references-count":128,"alternative-id":["10.3389\/fphar.2023.1225951"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1225951","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,21]]},"article-number":"1225951"}}